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1. Introduction 
Acinetobacter baumannii (A. baumannii) is an important opportunistic pathogen and causes a 
variety of nosocominal infections especially in Intensive Care Units (ICU’s) (Bergogne-
Berezin & Towner, 1996; Villegas & Harstein, 2003). These infections include bacteraemia, 
surgical-site infections, secondary meningitis, urinary tract infections and ventilator 
associated pneumonia (Bergogne-Berezin & Towner, 1996; Villegas & Harstein, 2003). 
Acinetobacter baumannii has multiresistant phenotypes, including resistance to broad-
spectrum β-lactams, fluoroquinolones, aminoglycosides and carbapenems and therefore 
treatment of this pathogen is complicated (Coelho et al., 2004; Dalla-Costa et al., 2003; Jeon 
et al., 2005; Landman et al., 2002; Naas et al., 2005; Vahaboglu et al., 2006; Zarrilli et al., 
2004). The multiresistant phenotypes of A. baumannii also contributed to the emergence of 
multi drug resistant Acinetobacter baumannii (MDRAB), which have become more prevalent 
within the past decade (Coelho et al., 2004) and has also caused an increase in the number of 
nosocomial infections in the past decade (Joly-Guillou, 2005). 
Over the last 20 years, there has been an increase in the interest of the Acinetobacter species 
(Giamarellou et al., 2008). The increase in interest is due to i) worldwide expansion of ICU’s, 
leading to a change in the types of infections caused by Acinetobacter spp and ii) due to the 
emergence of MDRAB and cases of pan-drug resistant A. baumannii (PDRAB) have also been 
reported (Giamarellou et al., 2008). 
The acquired carbapenem resistance in A. baumannii is often associated with carbapenemase 
production; IMP, VIM and SIM-type metallo-β-lactamase production or the OXA-24, OXA-
23 and OXA-58 type class D carbapenemases (Brown & Amyes, 2006; Poirel & Nordmann, 
2006). Also associated with acquired carbapenem resistance in A. baumannii is the over 
production of natural oxacillinase (OXA-51) (Poirel & Nordmann, 2006). 
Carbapenemases are the most versatile of all β-lactamases and many of them recognize 
almost all hydrolysable β-lactams (Livermore & Woodford, 2006; Nordmann & Poirel 2002; 
Walther-Rasmussen & Hoiby, 2006). Most carbapenemases are resistant to commercial β-
lactamase inhibitors (Livermore & Woodford, 2006; Nordmann & Poirel, 2002; Walther-
Rasmussen & Hoiby, 2006). Carbapenemases are divided into three subclasses on the basis 
of their hydrolysis characteristics (Frere et al., 2005). The first carbapenemases described 
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were from Gram-positive bacilli and were inhibited by EDTA (Frere et al., 2005). These 
carbapenemases were described as metalloenzymes and have one zinc atom in the active 
site (Frere et al., 2005). This zinc atom facilitates hydrolysis of a bicyclic β-lactam ring (Frere 
et al., 2005). The second form of carbapenemases use serine at the active sites and are 
inactivated by clavulanic acid and tazobactam (β-lactamase inhibitors) (Rasmussen et al., 
1996; Yang et al., 1990). Molecular classes A, C and D have serine in the active site and form 
part of the β-lactamases (Bush, 1988). The molecular class B of the β-lactamases are 
metalloenzymes and have zinc in the active site (Bush, 1988). The enzymes from the 
molecular classes A, B and D have the ability to hydrolyse carbapenems, which results in an 
elevated carbapenem minimum inhibitory concentration (Bush, 1988).  
The aim of this study was to optimise and evaluate multiplex polymerase chain reaction 
(PCR) assays to rapidly differentiate the four subgroups of the oxacillinase (OXA) genes and 
the five subgroups of the metallo-β-lactamase (MBL) antibiotic resistant genes. The PCR 
assays results were compared to the phenotypic tests i) Hodge test and ii) Double disk 
synergy test. Antibiotic resistance testing is important to decrease the spread of antibiotic 
resistant strains of A. baumannii in clinical settings. 
2. History of Acinetobacter baumannii 
Acinetobacter baumannii (Figure 1) was first isolated in 1911 from a soil sample by MW 
Beijerink (Kuo et al., 2004). Acinetobacter spp were first thought to be non-virulent 
saprophytes (Bergogne-Berezin & Towner, 1996). In the 1970s the widespread use and 
misuse of antibiotics started (Kuo et al., 2004). In 1986 Acinetobacter baumannii was 
taxonomically classified (Bouvet et al., 1986). The first carbapenem resistant A. baumannii 
(CRAB) isolates were discovered in 1991 (Kuo et al., 2004). The first carbapenem 
hydrolyzing oxacillinase (CHDL’s) was identified in 1995 (Scaife et al., 1995). It was initially 
named ARI-1 and was later renamed OXA-23 (Scaife et al., 1995). 
 
Fig. 1. Acinetobacter baumannii isolates (www.acinetobacter.org) 
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The first reported outbreak of CRAB occurred in the USA in 1991 (Go et al., 1994). 
Carbapenem Resistant A. baumannii isolates were isolated from a leukaemia patient in the 
oncology ward of a Taiwanese hospital in May 1998 (Hsueh et al., 2002). These isolates were 
observed to be resistant to almost all antibiotics e.g. cephalosporins, aztreonam, 
aminoglycosides and ciprofloxacin and were therefore named pan-drug resistant A. 
baumannii (PDRAB) (Hsueh et al., 2002). The rise in the number of multi drug resistant A. 
baumannii (MDRAB) strains has been due to the extensive use of antimicrobial 
chemotherapy against bacterial infections (Hsueh et al., 2002). 
3. Classification of Acinetobacter baumannii 
In 1986 Acinetobacter baumannii was taxonomically classified (Bouvet et al., 1986). 
Acinetobacter are grouped into three main complexes: i) Acinetobacter calcoaceticus-baumannii 
complex, which is glucose oxidizing and non-haemolytic; ii) Acinetobacter lwoffii, which are 
glucose negative and non-haemolytic and iii) Acinetobacter haemolyticus, which is haemolytic 
(Euzeby, 2008). The full classification of A. baumannii is listed in Table 1. 
 
Domain Bacteria 
Phylum Proteobacteria 
Class Gammaproteobacteria 
Order Pseudomonadales 
Family Moraxellaceae 
Genus Acinetobacter 
Species A. baumannii 
A. baylyi 
A. beijerinckii 
A. bouvetii 
A. calcoaceticus 
A. gerneri 
A. grimontii 
A. gyllenbergii 
A. haemolyticus 
A. johnsonnii 
A. junnii 
A. lwoffii 
A. parvus 
A. radioresistens 
A. schindleri 
A. soli 
A. tandoii 
A. tjernbergiae 
A. towneri 
A. ursingii 
A. venetianus 
14 species are still unnamed 
Table 1. Nomenclature of Acinetobacter baumannii (Euzeby, 2008) 
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There are 21 recognized genomic species of the genus Acinetobacter and 14 unnamed 
genomic species (Euzeby, 2008). 
4. General characteristics of Acinetobacter baumannii 
Acinetobacter baumannii are Gram-negative, non-fermentative, non-motile, oxidase-negative, 
aerobic coccobacilli that are ubiquitous in nature and commonly found within the hospital 
environment causing a variety of opportunistic nosocomial infections (Bergogne-Berezin et al., 
1996). The bacteria can be isolated from water, soil and the environment and from human skin 
(Bergogne-Berezin et al., 1996). The morphology of Acinetobacter spp is variable in Gram-
stained human clinical specimens and thus cannot be used to differentiate Acinetobacter from 
other causes of common nosocomial infections (http://microbewiki.kenyon.edu/index.php/ 
Acinetobacter_baumannii). Acinetobacter baumannii are non-lactose fermenting bacteria, 
however they partially ferment lactose on MacConkey agar (http://microbewiki.kenyon. 
edu/index.php/Acinetobacter_baumannii). All the species of the Acinetobacter genus grow 
well on MacConkey agar (except for A. lwoffii), when salt is absent (http://microbewiki. 
kenyon.edu/index.php/Acinetobacter_baumannii). Acinetobacter baumannii are strict 
aerobes and grow well on nutrient agar (http://microbewiki.kenyon.edu/index.php/ 
Acinetobacter_baumannii). Infection by A. baumannii is difficult to combat due to the Gram-
negative nature of the cell wall as the outer wall provides a barrier so that the antimicrobial 
agent is unable to enter the bacterial cell (Projan, 2004). 
Acinetobacter baumannii is an opportunistic pathogen that is successful in colonizing and 
persisting in the hospital environment and is able to resist desiccation (Getchell-White et al., 
1989; Jawad et al., 1996). The bacterium is also able to survive on inanimate surfaces for 
months (Kramer et al., 2006). Acinetobacter baumannii is among the most common causes of 
device related nosocomial infections (Dima et al., 2007; Thongpiyapoom et al., 2004), 
resulting when the bacterium is able to resist both physical and chemical disinfection, by 
forming a biofilm (Cappelli et al., 2003; Loukili et al., 2006; Pajkos et al., 2004). Biofilm 
associated proteins (BAP’s) were first characterized in S. aureus (Cucarella et al., 2001) and 
have been found in a number of other Gram-positive and Gram-negative pathogenic 
bacteria. 
4.1 Optimal Growth conditions for Acinetobacter baumannii 
Acinetobacter baumannii form part of the natural flora of the skin and mucous membranes of 
humans (Seifert et al., 1997). Acinetobacter baumannii are ubiquitous in clinical and natural 
environments and commonly colonises the skin, oropharynx secretions, respiratory 
secretions, urine, irrigating and intravenous solutions (Seifert et al., 1997). Acinetobacter 
baumannii can be cultured from sputum or respiratory secretions, wound and urine (Go & 
Cuhna, 1999). The pathogen colonises the gastro-intestinal tract and is associated with 
nosocomial meningitis, nosocomial pneumonia and bacteraemia (Go & Cuhna, 1999). 
Acinetobacter baumannii grown on trypticase soy agar produce circular, convex, smooth and 
slightly opaque colonies, which are 1.5 to 2.0 mm in diameter after 24 hours at 30°C or 3.0 to 
4.0 mm after 48 hours (Garrity et al., 2005). Acinetobacter baumannii do neither haemolyse 
horse blood nor sheep blood when grown on blood agar plates (Garrity et al., 2005). 
Seasonal variations have been reported for nosocomial A. baumannii infections and 
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bacteraemia, with increased incidences occurring in the summer months (McDonald et al., 
1999). 
5. Risk factors for Acinetobacter baumannii infections 
Acinetobacter baumannii can survive on various surfaces within hospitals, including catheters 
and other medical equipment (http://microbewiki.Kenyon.edu/index.php/Acinetobacter_ 
baumannii). Thus environmental contamination is an important source of infection as 
pathogens are spread directly from surfaces or through the hands of healthcare workers to 
patients (Corbella et al., 1996). Infected or colonized patients are important reservoirs of A. 
baumannii. Acinetobacter baumannii is passed from patient to patient via direct and indirect 
contact (D’Agata et al., 2000). The main risk factors of Acinetobacter baumannii bacteraemia 
are invasive procedures e.g. central venous catheterization, mechanical ventilation and 
surgery (Seifert et al., 1995b). Another major risk factor for A. baumannii infections is the 
widespread use of broad-spectrum antibiotics (Cisneros & Rodriguez-Bano, 2002). Other 
risk factors include prolonged hospital stay, ICU stay, enteral feeding, previous 
administration to another unit and previous use of third generation cephalosporins (Mulin 
et al., 1995; Scerpella et al., 1995). 
The risk factors within the ICU’s concern the immunosuppressed patients, patients 
previously exposed to antimicrobial therapy, patients who underwent high invasive 
procedures and patients who suffered from previous sepsis (Garcia-Garmendia et al., 2001). 
Other risk factors include pneumonia as a source of infection, inappropriate empirical 
treatment and prior treatment with carbapenems (Robenshtok et al., 2006). Surgical 
procedures performed within the emergency operating theatre is another major risk factor 
contributing to the spread of epidemic cases of A. baumannii, however the main risk factor 
was the previous use of fluoroquinolones (Villers et al., 1998). 
5.1 Pathogenesis of Acinetobacter baumannii 
Acinetobacter baumannii infections are associated with systems of high fluid content e.g. 
lungs, cerebrospinal fluid, peritoneal fluid and the urinary tract and usually only occur in 
the immunocompromised patients (Cuhna, 2007). Patients with A. baumannii bacteraemia 
usually have signs and symptoms that are related to the organ system involved (Cuhna, 
2007). Symptoms include wound infections, outbreaks of nosocomial pneumonia, catheter 
associated bacteriuria, urethritis and continuous ambulatory peritoneal dialysis (CAPD) 
associated peritonitis (Cuhna, 2007). Bacteraemia results in septic shock in 25-30% of all 
cases and disseminated intravascular coagulation frequently occurs (Cisneros et al., 1996: 
Seifert et al., 1997). Colonisation may occur after an invasive infection (Corbella et al., 1996), 
especially in burn patients (Wisplinghoff et al., 2004). Problems rarely associated with A. 
baumannii infections include meningitis, endocarditis, urinary tract infections, pneumonia 
and cholangitis (Cuhna, 2007). Other problems that rarely occur are soft tissue infections 
and complicated skin, abdominal infections and central nervous system (CNS) infections 
(Fournier & Richet, 2006). Allen and Green documented the first report of airborne spread of 
A. baumannii in 1987. Acinetobacter baumannii survives much better on fingertips or on dry 
surfaces when tested under stimulated hospital environmental conditions (Jawad et al., 
1996). The skin of patients and medical personnel is involved in the transmission of A. 
baumannii strains and in some outbreaks; molecular typing has identified the epidemic 
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strain on the skin of the patients (Gerner-Smidt, 1987; Patterson et al., 1991). Contaminated 
reusable medical equipment e.g. ventilator tubing, respirometers and arterial pressure 
monitoring devices are used for the management of severely ill patients serve as another 
route of transmission to patients (Beck-Sague et al., 1990; Cefai et al., 1990). Fomites e.g. bed 
mattresses (Sheretz & Sullivan., 1985), pillows (Weernink et al., 1995), a tape recorder, 
television set and a fan (Jawad et al., 1994) were found to be contaminated with Acinetobacter 
and served as reservoirs during nosocomial outbreaks.  
The mortality rate within the hospitals is high, with a 23% mortality recorded for 
hospitalized patients and a 43% mortality rate among patients in intensive care (Falagas et 
al., 2006). The Antimicrobial Availability Task Force (AATF) of the Infectious Disease 
Society of America identified Acinetobacter baumannii, Aspergillus spp, extended spectrum β-
lactamase producing Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus aureus as 
“particularly problematic pathogens” and there is a desperate need for new drug 
development (Talbot et al., 2006). 
It is difficult to distinguish between colonization and infection regarding A. baumannii (Joly-
Guillou, 2005). There is controversy over whether infections caused by A. baumannii result in 
unfavourable outcomes (Blot et al., 2003; Falagas et al., 2006). The isolation of A. baumannii 
in hospitalized patients is an indicator of severe illness with an associated mortality of 
approximately 30% (Wilson et al., 2004). 
Community acquired A. baumannii (CAAB) occurs within an individual with one or more 
cultures of blood, collected within 48 hours of admission, that is positive for A. baumannii 
complex and is identified by a biochemical method (API 20NE system) (bioMerieux, France) 
(Schreckenberger & Von Graevenitz, 2000). Patients with CAAB associated pneumonia had 
an increased mortality rate and presented with a more severe disease than the patients 
without pneumonia (Wang et al., 2002). The development of CAAB is associated with 
underlying malignancies e.g. lung cancer, lymphoma and thymic carcinoma (Wang et al., 
2002). Acinetobacter baumannii genomic species were responsible for CAAB; however there is 
no evidence of clonal spread of A. baumannii in the community (Wang et al., 2002). 
Carbapenems, cefopirome, cefepime, ceftazidime, aminoglycosides and fluoroquinolones 
are the antimicrobials of choice for treating CAAB (Wang et al., 2002). 
5.2 Virulence factors of Acinetobacter baumannii strains 
Acinetobacter baumannii have very few virulence factors (Cisneros & Rodriguez-Bano, 2002), 
however some strains have virulence factors associated with invasiveness, transmissibility 
or the enhanced ability to colonise immunocompromised patients (Dijkshoorn et al., 1996). 
Ethanol stimulates the virulence of A. baumannii (Smith et al., 2004), which led to the 
identification of a number of genes, affecting virulence towards Caenorhabditis elegans and 
Dictyostelium discoideum (Smith et al., 2007). 
A new strain (OXA-23 clone II) was identified in a military hospital and was found to be a 
particularly virulent strain, which is very difficult to eliminate from medical facilities 
(promedmail). There are three major European clones of A. baumannii (Giamarellou et al., 2008) 
Clone I, found in South Africa, Czech Republic, Poland, Italy and Spain; Clone II, found in 
South Africa, Spain, Turkey, Greece and France and clone III is found in the Netherlands, Italy, 
France and Spain (Van Dessel et al., 2004). Clones I and II are responsible for the outbreaks of 
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A. baumannii bacteraemia in South Africa and Northern Europe (Van Dessel et al., 2004). 
Acinetobacter can efficiently transfer genes horizontally (only observed and analysed in A. 
baylyi), especially the genes encoding antibiotic resistance (Gerischer, 2008). 
A large portion of the A. baumannii genome is dedicated to pathogenesis, with a large 
number of genes occurring within virulence islands (Perez et al., 2007). Acinetobacter 
baumannii together with Acinetobacter DNA group13TU is involved in the majority of 
Acinetobacter hospital outbreaks (Bergogne-Berezin & Towner, 1996). Strains of the 
Acinetobacter DNA group 3 and A. junii have only occasionally been implicated in outbreaks 
of nosocomial infections (Bernards et al., 1997). Acinetobacter baumannii has environmental 
resilience and a wide range of resistance determinants, therefore making it a successful 
nosocomial pathogen (Nordmann, 2004). Acinetobacter baumannii has caused numerous 
global outbreaks and displayed ever increasing rates of resistance (Villegas & Harstein, 
2003). In hospital outbreaks the emergence of imipenem-resistant strains has been 
documented (Brown et al., 1996; Go et al, 1994). 
6. Clinical manifestations of Acinetobacter baumannii infections 
The clinical manifestations of A. baumannii are non-specific and present as a trans-
maculopapular rash affecting the palms of the hands and the soles of the feet of endocarditis 
patients, or necrotic lesions of the skin and soft tissue (Seifert et al., 1995). Acinetobacter 
baumannii bacteraemia is polymicrobial, and is often associated with Klebsiella pneumoniae 
(Seifert et al., 1995). 
6.1 Treatment of Acinetobacter baumannii infections 
Acinetobacter baumannii are Gram-negative bacteria and therefore are particularly difficult to 
treat due to the presence of an outer membrane (Projan, 2004). The recommended treatment 
therefore is a limited spectrum active β-lactam e.g. ceftazidime or imipenem the most active 
agent against A. baumannii and an aminoglycoside (Cisneros & Rodriguez-Bano, 2002). 
There is incomplete current knowledge of the clinical response and bacterial mechanisms of 
resistance to antimicrobials (Kahlmeter et al., 2006). The reliability and comparability of 
different methods of susceptibility testing e.g. disc diffusion and broth microdilution have 
not been consistent for A. baumannii (Swenson et al., 2004). The persistence of subtle growth 
beyond an obvious end point by broth microdilution is of great concern in the case of β-
lactams, which therefore explains its poor reaction with the disc diffusion method (Swenson 
et al., 2004). Doripenem, a novel carbapenem is active against susceptible A. baumannii 
(Fritsche et al., 2005; Jones et al., 2004; Jones et al., 2005; Mushtaq et al., 2004). Doripenem 
was not effective against A. baumanni isolates producing blaOXA-23 or blaIMP-4 or metallo-β-
lactamases (Mushtaq et al., 2004). 
6.2 Carbapenems as treatment for Acinetobacter baumannii infections  
Carbapenems are structurally related to the penicillins (“penams”), differing only by the 
substitution of carbon (“carba”) for the sulfur atom at position 1 and the presence of a 
double bond between C2 and C3 (Bradley, 1997; Wise, 1986). A hydroxyethyl side chain 
instead of the acylamino group found in penicillins and cephalosporins is present and 
provides resistance to most β-lactamases (Bradley, 1997; Wise, 1986).  
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Carbapenems were introduced into clinical practice in the 1970’s and the 1980’s marked the 
emergence of Gram-negative bacterial resistance to carbapenems (Nordmann & Poirel, 2002; 
Walsh, 2005). Carbapenems were derived from the naturally occurring antibiotic, 
thienamycin, which is produced by the soil microorganism Streptomyces cattleya (Jacobs, 
1986). The first carbapenemases described were from Gram-positive bacilli and were 
inhibited by EDTA (Frere et al., 2005). Carbapenems are recognised as the gold standard for 
treating infections caused by resistant Gram-negative bacteria (Rahal, 2006). 
6.3 Combination therapy as a strategy for the treatment of multiple drug resistant 
Acinetobacter baumannii  
Sulbactam is an inhibitor of β-lactamases and has in vitro bactericidal activity against 
Acinetobacter spp (Cisneros & Rodriguez-Bano, 2002). The efficacy of sulbactam against 
susceptible A. baumannii is similar to imipenem (Rodriguez-Hernandez, 2000). Sulbactam 
exhibits bacteriostatic action against A. baumannii (Corbella et al., 1998). Sulbactam is also 
used to treat meningitis caused by multiple drug resistant Acinetobacter baumannii (MDRAB) 
(Cisneros & Rodriguez-Bano, 2002). Combinations of sulbactam with aminoglycosides, 
rifampin and azithromycin have demonstrated synergy against imipenem susceptible 
strains (Appleman et al., 2000; Savov et al., 2002). There is little or no advantage to the 
combination sulbactams with cephalosporins (Appleman et al., 2000; Savov et al., 2002). 
Polymyxins (colistimethate and polymyxin B) are the only alternative treatment for sulbactam 
resistant A. baumannii strains (Wood & Reboli, 1993). Colistin was used in the 1960’s and the 
1970’s, but had many adverse side effects, including nephrotoxicity, neuro-muscular blockage 
(Cisneros & Rodriguez-Bano, 2002). Colistin disrupts the outer cell membranes of many Gram-
negative bacilli by changing the permeability of the membrane and causing a bactericidal 
effect (Cisneros & Rodriguez-Bano, 2002). Colistin is only recommended for patients who have 
no other treatment alternatives (Cisneros & Rodriguez-Bano, 2002). Rifampicin combined with 
colistin or sulbactam acts synergistically against MDRAB (Hogg et al., 1998). 
7. Mechanisms of antibiotic resistance in Acinetobacter baumannii 
The general mechanisms of resistance are enzyme-mediated resistance, genetic adaption, 
efflux pumps and changes in the structure of outer membrane components (Cloete, 2003). 
Enzyme mediated resistance is the ability of the bacteria to produce enzymes that transform 
the antibiotics into non-toxic or inactivated forms (Ma et al., 1998). Efflux pumps involve a 
large number of seemingly unrelated (structurally) compounds, pumped out of the cell, 
which lowers the concentration of the drug within the cell and therefore prohibits the drug 
to take proper effect (Nikaido, 1996). Changes in the structure of the outer membrane and its 
components e.g. porins and alterations in the penicillin binding proteins (PBP’s), allows for 
the cells to develop resistance to antimicrobials on the basis of exclusion because the drugs 
are no longer able to penetrate the cells and therefore the drugs can’t reach their intended 
site of action in the cell (Cloete, 2003). 
Acinetobacter baumannii has become resistant to many classes of antibiotics and is well suited 
for genetic exchange (Lorenz & Wackernagel, 1994; Metzgar et al., 2004). Acinetobacter 
baumannii are among a unique class of Gram-negative bacteria that are described as 
“naturally transformable” (Lorenz & Wackernagel, 1994; Metzgar et al., 2004). Acinetobacter 
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strains lack the mutS gene, which is part of the mismatch repair system that preserves 
genetic stability and exhibits increased mutation rates (Young & Ornston, 2001). It is 
unknown whether A. baumannii are naturally competent or whether through the alteration 
of environmental conditions facilitates pathogenicity or antibiotic resistance gene acquisition 
(Fournier et al., 2006). The key resistance genes identified were those coding for VEB-1, 
AmpC, and OXA-10 beta-lactamases, various amino glycoside-modifying enzymes (AME) 
and those genes encoding for the tetracycline efflux pumps (Fournier et al., 2006). 
Plasmids, transposons and the bacterial chromosome are involved in antibiotic resistance 
within A. baumannii (Bergogne-Berezin & Towner, 1996). Carbapenemases occurring within 
A. baumannii belong to the class D family of serine-β-lactamases or the imipenemase 
(IMP)/Verona integrase (VIM) class B family of metallo-β-lactamases (Brown & Amyes, 
2006). Imipenem is the most active drug against A. baumannii (Cisneros & Rodriguez-Bano, 
2002). Resistance to carbapenems is associated with reduced drug uptake due to porin 
deficiency and reduced affinity for the drug due to modification of the PBP’s by mutations 
(Clark, 1996). 
Acinetobacter baumannii’s largest virulence island contains genetic elements, which are 
homologous to the type IV secretion systems of Legionella and Coxiella burnetti (Goldstein et 
al., 1983). Over 25 years ago A. baumannii was observed to acquire antimicrobial resistance 
factors through conjugation of plasmids (Goldstein et al., 1983). Transposons are important 
in the dissemination of genetic determinants of resistance in Acinetobacter spp (Devaud et al., 
1982; Palmen & Hellingwerf, 1997) and many of the transposons contain integrons, 
predominantly from class I. Integrons contain an int gene and gene cassettes that can be 
mobilized to other integrons or to secondary sites in the bacterial genome (Poirel et al., 
2005).  
A multi drug resistant (MDR) phenotype in A. baumannii occurs when integron-born 
resistance determinants acting against different classes of antibiotics co-exist, giving rise to 
MDR gene cassettes (Seward, 1999; Yum et al., 2002). Insertion sequences (IS), which 
promote gene expression, have played an important role in explaining the regulation of 
resistance (Segal et al., 2005). The ISAba1 element found in A. baumannii but not in 
Enterobacteriaceae or in Pseudomonas aeruginosa (Segal et al., 2005), results in the over 
expression of Amp C and OXA-51/OXA-69-like beta–lactamases and in decreased levels of 
susceptibility to ceftazidime and carbapenems (Heritier et al., 2006). 
7.1 Oxacillinase (OXA) genes in Acinetobacter baumannii  
Carbapenemases are classified into four major functional groups (groups 1 to 4) with multiple 
subgroups of group 2 that are differentiated according to a group specific inhibitor or substrate 
profiles (Bush et al., 1995). According to this classification scheme carbapenemases are found 
primarily in group’s 2f and 3 (Nordmann et al., 1993; Yang et al., 1990). 
Class D carbapenemases are classified into four subgroups (Vahaboglu et al., 2006). 
Subgroup 1, the OXA-23 group (including OXA-27 and OXA-49), are the plasmid encoded 
genes (Vahaboglu et al., 2006). The OXA extended spectrum beta-lactamases are able to 
hydrolyze extended spectrum cephalosporins (Aubert, 2001; Walther-Rasmussen & Hoiby, 
2006). The OXA-23 was the first OXA carbapenemase (OXA β-lactamases that inactivate 
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carbapenems) within A. baumannii obtained from a clinical isolate (Aubert, 2001; Walther-
Rasmussen & Hoiby, 2006). The OXA-23 genes originated in A. radioresistens (Turton et al., 
2005). This plasmid-encoded enzyme was found in 1985 in Scotland before the introduction 
of carbapenems (Paton et al., 1993). It was initially named “Acinetobacter resistant to 
imipenem” (ARI-1) and has been discovered in Brazil, England, Polynesia, Singapore, Korea 
and China (Brown & Amyes, 2006; Jeon et al., 2005). Subgroup 2 is the OXA-24 group 
(including OXA-25, OXA-26 and OXA-40), which is chromosomally encoded (Vahaboglu et 
al., 2006). The OXA-24 carbapenemase has a crystal structure and therefore suggests a novel 
catalytic role for Tyr112 and Met223 side chains (Santillana et al., 2007). Subgroup 1 and 2 
share 60% identity (Heritier et al., 2005b). 
Subgroup 3 consists of OXA-51 and its variants, which are chromosomally encoded 
(Vahaboglu et al., 2006). The OXA-51/69 expression varies according to the presence of 
ISAba1 (Poirel & Nordmann, 2006). The OXA-51 gene was first detected in Argentina in 2005, 
within genetically distinct A. baumannii isolates (Brown & Amyes, 2005). Subgroup 3 has 
56% identity with subgroup 1 and 61% to 62% identity with subgroup 2 (Brown et al., 2005). 
Subgroup 4 contains OXA-58, which is a plasmid-encoded gene (Vahaboglu et al., 2006) and 
was first detected in Toulouse (France) in 2003 (Heritier et al., 2005a; Poirel et al., 2005). 
Subgroup 4 shares less than 50% homology with the other three groups (Poirel et al., 2005). 
The OXA-58 gene is rapidly disseminating and those isolates, which contain both OXA-51-
type and OXA-58 genes, are pandrug-resistant A. baumannii (PDRAB) (Coelho et al., 2006). 
The plasmid borne carbapenemase, OXA-58, was found in France, England, Argentina, 
Spain, Turkey, Romania, Austria, Greece, Scotland and Kuwait (Coelho et al., 2006; Marque 
et al., 2005; Pournaras et al., 2006). It is uncertain whether these genes are acquired or occur 
naturally in A. baumannii (Brown & Amyes, 2006). In A. baumannii isolates with OXA-51 as 
the sole carbapenemase, carbapenem resistance was associated with an insertion sequence 
ISAbaI and it is thought that this might be the promoter for the hyper-production of β-
lactamase genes (Turton et al., 2006). 
Bacteria producing carbapenemase enzymes have a reduced susceptibility to imipenem 
(Ambler et al., 1991). However, the minimum inhibitory concentration (MIC) of imipenem 
can range from mildly elevated to fully resistant (Ambler et al., 1991). Therefore, these β-
lactamases may not be recognised following routine susceptibility testing (Ambler et al., 
1991). Βeta-lactamases have the ability to hydrolyse carbapenems, resist commercially 
available β-lactamase inhibitors and are susceptible to inhibition by metal ion chelators (Lim 
et al., 1988). The widespread presence of oxacillinases and their division into distinct 
subgroups, indicates that these enzymes are an essential component of the genetic makeup 
of Acinetobacter spp (Walther-Rasmussen & Hoiby, 2006). The OXA enzymes as emerging 
carbapenemases are increasingly associated with outbreaks of A. baumannii containing OXA-
40 and OXA-58 in the United States (Hujer et al., 2006; Lolans et al., 2006). The OXA-51/69-
like beta-lactamase is a “naturally occurring” chromosomal enzyme in Acinetobacter 
baumannii and has been found in isolates from four continents (Heritier et al., 2005a). 
7.2 Metallo--lactamase (MBL) genes in Acinetobacter baumannii  
Metallo--lactamases form part of the class B -lactamases, capable of hydrolyzing 
carbapenems and other -lactam antibiotics except for aztreonam (Walsh et al., 2005; Walsh, 
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2005). Class B -lactamases differ from class A and class D carbapenemases by having a 
metal ion, zinc, in their active site, which participates in catalysis (Walsh et al., 2005; Walsh, 
2005). There are five types of metallo--lactamases (MBL’s) that have been identified in A. 
baumannii (Brown & Amyes, 2006). The most common metallo-β-lactamases include 
“Verona integron-encoded metallo-β-lactamases” (VIM), “Imipenem hydrolyzing β-
lactamase”(IMP), “German Imipenemase” (GIM), Seoul imipenemase (SIM) and Sao Paulo 
metallo-β-lactamases (SPM-1) enzymes, which are located on a variety of integron structures 
and are incorporated as gene cassettes (Brown & Amyes, 2006). The integration of the 
integron on the plasmids or transposons allows for facilitated transfer between bacteria 
(Watanabe et al., 1991).  
Imipenem (IMP) metallo--lactamases were first described in a P. aeruginosa strain found in 
Japan in 1988 (Watanabe et al., 1991). Metallo--lactamases is not the predominant 
carbapenemases found within A. baumannii however the following carbapenemases have 
been described: IMP-1, IMP-2, IMP-4, IMP-5, IMP-6, and IMP-11 (Walsh et al., 2005; Walsh, 
2005). The IMP type MBL’s have stronger carbapenem-hydrolysing activity than the OXA-
type--lactamases (Laraki et al., 1999). The VIM, IMP, SPM, and GIM genes are found on 
cassettes in class 1 integrons, although IMP genes have also been found on class 3 integrons 
(Collis et al., 2002). Watanabe et al. (1991) reported the detection of IMP-1, located on an 
integron situated on a conjugative plasmid, in Serratia marcescens and other Enterobacteriaceae 
in Japan. The imipenem-hydrolyzing β-lactamase has been detected in rare clinical isolates 
of Enterobacter cloacae in Argentina, the USA and France (Nordmann et al., 1993; 
Pottumarthy et al., 2003; Radice et al., 2004; Rasmussen et al., 1996). 
Imipenem hydrolyzing β-lactamase contains the conserved active site motifs S-X-X-K, S-D-N 
and K-T-G of the class A β-lactamases (Aubron, 2005; Yu et al., 2006). The carbapenemases 
have conserved cysteine residues at positions 238 and 69 that form a disulfide bridge 
(Aubron, 2005; Yu et al., 2006). Genes encoding IMP-2 β-lactamases were found on plasmids 
in Enterobacter asburiae isolated from river water in the US and on plasmids from an E. 
cloacae isolated from China (Aubron, 2005; Yu et al., 2006). The disulfide bond is necessary 
for the hydrolytic activity and is used to stabilize the enzyme structurally (Majiduddin & 
Palzkill, 2003; Sougakoff et al., 2002). The mechanism of cleavage of the -lactam ring is 
different for MBL’s as compared to -lactamases, however, both gene products still share a 
unique  fold in the active sites of the enzymes (Ullah et al., 1998). The blaIMP is a foreign 
gene that is introduced from another species of bacteria and A. baumannii only retain the 
gene in environments where there is selective pressure in the form of the presence of 
imipenem (Takhashi et al., 2000). 
Pandrug-resistant A. baumannii (PDRAB) are resistant to nearly all the commercially 
available antibiotics including amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, 
gentamycin, imipenem, meropenem, ofloxacin, ticarcillin-clavulanate and piperacillin-
tazobactam (Hsueh et al., 2002). Carbapenem-resistant A. baumannii are usually susceptible 
to ciprofloxacin, ofloxacin, gentamycin or amikacin (Hsueh et al., 2002). Increasing the use of 
carbapenems and ciprofloxacin has contributed to the development and spread of PDRAB 
strains (Hsueh et al., 2002). 
Verona integron-encoded MBL (VIM-1) was first identified in Italy in 1997 in a P. aeruginosa 
isolate (Lauretti et al., 1999). Acinetobacter baumannii containing the VIM-2 gene has been 
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reported only in Korea (Yum et al., 2002). Acinetobacter baumannii isolates producing 
metallo--lactamases from Korea were reported to be incredibly diverse, containing Seoul 
imipenemase (SIM-1), which is a novel metallo--lactamase (Lee et al., 2005). 
7.3 Non-enzymatic mechanisms of antibiotic resistance 
In A. baumannii isolates from Madrid the loss of the 22-kDa and 33-kDa outer membrane 
proteins combined with the production of OXA-24, resulted in resistance to carbapenems 
(Bou et al., 2000). A homologue of OprD, a 43-kDa protein was identified in A. baumannii 
(Dupont et al., 2005). The 43-kDa protein is a well studied porin, which is frequently 
associated with imipenem resistance in P. aeruginosa (Dupont et al., 2005). Confirming 
resistance to imipenem and meropenem in A. baumannii is the channel formation of CarO, a 
29-kDa outer membrane protein (Limansky et al., 2002; Mussi et al., 2005; Siroy et al., 2005). 
Reduced expression of PBP-2 within isolates from Seville, Spain explained the resistance of 
A. baumannii to carbapenems (Fernandez-Cuenca et al., 2003). 
7.3.1 Efflux pumps as mechanisms of resistance in Acinetobacter baumannii 
Efflux pumps cause resistance against several different classes of antibiotics and mediate the 
efflux of compounds that are toxic to the bacterial cell, including antibiotics, in a coupled 
exchange with protons (Poole, 2005). The distinct families of efflux pumps the major 
facilitator superfamily, the small multidrug resistance superfamily, the multidrug and toxic 
compound extrusion superfamily and the resistance-nodulation-cell division family are 
found in various species of bacteria (Poole, 2005). Over expression of the AdeABC efflux 
pump, which forms part of the resistance-nodulation-cell division family, confers high-level 
resistance to carbapenems, together with carbapenem-hydrolyzing oxacillinase (Marque et 
al., 2005). The mechanism, which controls the expression of the efflux pump, functions as a 
two-step regulator (adeR) and sensor (adeS) system (Marchand et al., 2004). A single point 
mutation within the adeR and adeS genes results in increased expression and increased efflux 
(Marchand et al., 2004). 
8. Resistance of Acinetobacter baumannii to various antibiotics 
Resistance to aminoglycosides is mediated by aminoglycoside-modifying enzymes (AME’s) 
(Perez et al., 2007). Examples of such enzymes include aminoglycoside phosphotransferases 
(aph), aminoglycoside acetyltransferases (acc) and aminoglycoside adenyltransferase (aad) 
(Perez et al., 2007). Acinetobacter baumannii have transposon mediated efflux pumps, which 
involves tetracycline A (Tet) and TetB (Guardabassi et al., 2000). Tetracycline A allows for 
the efflux of tetracycline, while TetB allows for the efflux of both tetracycline and 
minocycline (Huys et al., 2005). The other mechanism of resistance to the tetracyclines is due 
to the ribosomal protection protein (Perez et al., 2007). The ribosomal protection protein is 
encoded by the tetracycline M gene and protects the ribosome from the action of 
tetracycline, minocycline and doxycline (Ribera et al., 2003). 
Modification in the structure of the DNA gyrase decreases the affinity of the enzyme to 
quinolones (Seward & Towner, 1998); therefore A. baumannii becomes resistant to 
quinolones (Perez et al., 2007). Modifications of the lipopolysaccharides (LPS’s) in A. 
baumannii cause the bacterium to become resistant to polymyxins (Perez et al., 2007). 
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Modifications to the LPS in A. baumannii include acylation, presence of antigens and 
acidification, which all interfere with the binding of the polymyxins to the cell membrane 
(Peterson et al., 1987). 
9. Spread and control of Acinetobacter baumannii 
Infection control is critical concerning A. baumannii given its ability to cause outbreaks 
(Boyce & Pittet, 2002; Pittet, 2004). Contact precautions, hand washing and alcohol hand 
decontamination are rarely applied however are universally encouraged and important 
(Boyce & Pittet, 2002; Pittet, 2004). However, the applications of meticulous environmental 
decontamination and aggressive chlorhexidine baths as temporary measures to control 
outbreaks are the favourable approach (Maragakis et al., 2004; Wilks et al., 2006). However 
these methods are expensive, labour-intensive and must be clinically proven through trials 
(Maragakis et al., 2004; Wilks et al., 2006). The key to infection control measures lies within 
preventing dissemination of MDR clones (Maragakis et al., 2004; Wilks et al., 2006). The use 
of molecular tools for investigation of outbreaks to establish clonality among isolates allows 
for a more effective implementation of infection control measures and aids in the 
identification of environmental sources (Maragakis et al., 2004; Wilks et al., 2006). 
Polymerase Chain Reaction followed by electronspray ionization mass spectrometry and 
base composition analysis are used to determine clonality (Ecker et al., 2006; Hujer et al., 
2006). Restriction of the use of especially broad-spectrum activity antibiotics is necessary for 
infection control strategies (Chakravarti et al., 2000; Hughes, 2003). The refinement of 
genomic and proteomic techniques represents hope for the discovery of new antimicrobials 
active against MDR organisms and for the development of vaccines (Chakravarti et al., 2000; 
Hughes, 2003). The success of these and other approaches for the containment of MDR A. 
baumannii depends on the commitment of clinical practitioners, scientists, hospitals and 
public health administrators and on the support of the informed public (Chakravarti et al., 
2000; Hughes, 2003). 
10. Diagnosis and detection of Acinetobacter baumannii 
Monitoring the geographical spread of virulent or epidemic pathogens is achieved through 
the identification and typing of bacteria (Grundmann et al., 1997). Traditional methods for 
the identification of A. baumannii are unsatisfactory (Gerner-Smidt et al., 1991), due to the 
difficulty in distinguishing A. baumannii from A. calcoaceticus phenotypically (Giamarellou et 
al., 2008). Acinetobacter baumanni is predominantly diagnosed from sputum, blood, central 
venous catheter tips, pleural fluid, wound pus, bronchial washing and urine (Hsueh et al., 
2002). 
10.1 Direct phenotypic detection of Acinetobacter baumannii  
Phenotypic methods of detecting A. baumannii include growing the isolates on fluorescence-
lactose-denitrification media (FLN) in order to determine the amount of acid produced by 
the metabolism of glucose (http://microbewiki.kenyon.edu/index.php/Acinetobacter 
baumannii). This method is used to differentiate the respective species within the Acinetobacter 
genus (http://microbewiki.kenyon.edu/index.php/Acinetobacter_baumannii). Crude 
enzyme extracts and -lactamase activity assays are other phenotypic methods used to 
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detect antibiotic resistant strains of A. baumannii (Takahashi et al., 2000). Biochemical tests 
used to differentiate A. baumannii from other species of the Acinetobacter genus include the 
following: haemolysis test (-), histamine assimilation test (-), glucose oxidation test, citrate 
assimilation test (+), gelatin liquefaction test (-) (Prashanth & Badrinath, 2000). 
10.1.1 Automated detection of Acinetobacter baumannii 
A Vitek GNI card (bio Mérieux, France) is used for the detection of carbapenemase activity 
in clinical isolates. The results of the Vitek test are confirmed using the API 20NE system 
(bio Mérieux, France) (Clinical and Laboratory Standards Institute, 2009). 
10.1.2 Manual methods of detection of Acinetobacter baumannii 
The E-test (AB Biodisk, Sweden) is used to identify metallo--lactamase production by 
determining the minimum inhibitory concentration (MIC), which allows for the detection of 
the production of VIM or IMP enzymes (Walsh, 2005). Susceptibility testing can be performed 
using broth microdilution according to Clinical and Laboratory Standards Institute standards 
(2009) and the Kirby-Bauer double disk synergy test (Peleg et al., 2005). The disk 
approximation test with 2-mercaptopropionic acid or EDTA is used to screen for metallo-β-
lactamase producers (Arakawa, 2000; Yong et al., 2006). Ethylenediaminetetraacetic acid 
(EDTA) is a chelator of Zn2+ and other divalent cations and therefore inhibits the metallo-β-
lactamases that have zinc ions in their active sites (Lim et al., 1988). 
The imipenem (IMP)-EDTA double-disk synergy test (DDST) can distinguish metallo-β–
lactamase producing from metallo-β–lactamase non-producing Gram-negative bacilli (Lee et 
al., 2001). However, occasional isolates show false negative results due to a deficiency of zinc 
within the isolate’s active site (Yigit et al., 2001). The test can be improved by using an IMP 
disk to which 10 µl of 50 mM zinc sulfate (140 µg/disk) has been added, to compensate for 
the lack of zinc or by using Mueller-Hinton agar to which zinc sulfate has been added to a 
final concentration of 70 μg.ml-1 (Yigit et al., 2001). 
The Hodge test is a simple method for screening metallo-β-lactamase producing isolates of 
Gram-negative bacilli (Lee et al., 2001). The Hodge test/cloverleaf test is a microbiological 
assay of carbapenemase activity, where an extract of the whole cell or the suspected isolates 
are tested against imipenem on an agar plate (Hornstein et al., 1997). It  is unnecessary to 
test an isolate for a carbapenemase using the modified Hodge test when all of the 
carbapenems that are reported by a laboratory test are either intermediate or resistant 
(Clinical and Laboratory Standards Institute, 2009). However, the modified Hodge test is 
used for infection control and epidemiological purposes (Clinical and Laboratory Standards 
Institute, 2009). The imipenem disk test is a poor screening method for carbapenemases 
(Clinical and Laboratory Standards Institute, 2009). 
10.2 Molecular detection of Acinetobacter baumannii 
Molecular methods based on PCR for the detection of carbapenemase producing genes are 
used due to the problems with the direct phenotypic detection methods e.g. difficulty in 
distinguishing between species of the Acinetobacter genus (Vaneechoutte, 1996). The 
molecular methods include a PCR with primers for detecting OXA-23, OXA-24, OXA-51, 
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OXA-58, IMP-1, IMP-2, IMP-4, VIM-1, VIM-2, SPM-1, GIM-1, and SIM-1 genes can be used 
to detect all families and subgroups of the presumed carbapenemases (Petropoulou et al., 
2006). The genotypic tests used to determine the clonal relatedness of the isolates include, 
Random amplified polymorphism DNA (RAPD PCR)-fingerprinting with the primers M13, 
Enterobacterial Repetitive Intergenic Consensus (ERIC2) and Pulsed Field Gel Electrophoresis 
(PFGE) using the ApaI enzyme can be performed (Seifert et al., 2005). The main advantages 
of the molecular techniques in comparison with the traditional phenotypic methods are high 
reproducibility and applicability to a wide variety of bacteria and time saving (Grundmann 
et al., 1997). 
10.3 Indirect diagnosis of Acinetobacter baumannii 
Gram-negative bacteria contain lipopolysaccharides (LPS’s) on their outer membranes, 
which consist of covalently linked lipid A (anchors the LPS into the outer membrane) and 
the core polysaccharide (O-polysaccharide or O-antigen), which is linked to the lipid A 
(Pantophlet et al., 1999). The type of LPS found within A. baumannii has the smooth or S-
form phenotype and can be used in clinical microbiology laboratories for clinical research 
purposes (Pantophlet et al., 1999). 
11. Materials and methods 
Ninety-seven imipenem/meropenem resistant A. baumannii isolates were collected between 
March and April 2009 from a Tertiary Academic hospital. These isolates were all given a 
unique number. The A. baumannii isolates were analysed by the Diagnostic Division of the 
department of Medical Microbiology, National Health Laboratory service (NHLS) at the 
University of Pretoria. The isolates were identified as A. baumannii and underwent 
susceptibility testing. The Vitek 2 (bioMérieux, France) automated system was used to 
phenotypically test for the presence of carbapenemases within the A. baumannii isolates. 
Ninety-seven imipenem/meropenem resistant isolates were streaked out onto 5% sheep 
blood agar plates (Diagnostics Media Products, NHLS, South Africa). The plates were 
incubated (Horo incubator) overnight at 37ºC. Gram-staining was performed for each 
isolate. (2002). Brain-Heart infusion broth (Biolab, Wadeville, South Africa) was prepared 
and aliquoted into Bijou culture bottles before sterilization. The broth bottles were 
inoculated from overnight plate cultures of A. baumannii grown on 5% sheep blood agar 
(Diagnostic Media Products, NHLS, South Africa) by adding 3 to 4 colonies of an isolate into 
the broth. The inoculated broths were incubated in a Labcon shake incubator at 37°C 
overnight. A volume of 900 µl of the inoculated turbid broth and 900 µl of sterile glycerol 
was added to a sterilized cryotube and were stored at -70°C. The CLSI (2009) guidelines for 
the performance of the modified Hodge test and for the double disk synergy test were 
followed for the detection of carbapenemase production. 
A MagNA Pure Compact Nucleic Acid Isolation Kit 1 (Roche, Germany) was used to 
perform automated whole cell DNA extraction according to the manufacturer’s guidelines. 
A volume of 400 µl of each of the A. baumannii broth culture samples was added to a Magna 
Pure sample tube for automated DNA extraction. Sealed cartridges with the necessary 
reagents were added to each lane. The purified nucleic acids (100 μl of pure A. baumannii 
www.intechopen.com
 Antibiotic Resistant Bacteria – A Continuous Challenge in the New Millennium 228 
DNA) were eluted and stored at -20°C for further analysis. The Nanodrop 
Spectrophotometer ND-1000 instrument was used to measure the DNA concentration for 
each of the samples. 
Two multiplex PCR assays: 1) Multiplex PCR I reaction of OXA-23, OXA-24, OXA-51 and 
OXA-58 genes (Woodford et al., 2006) and 2) Multiplex PCR II reaction of IMP, VIM, GIM-1, 
SPM-1 and SIM-1 genes (Ellington et al., 2007) were performed using the QIAGEN 
Multiplex PCR 1000 kit (Promega, Madison, USA), which was set up according to the 
manufacturer’s guidelines. The QIAGEN Multiplex PCR 1000 kit contains Multiplex PCR 
Master mix, RNAse free water and Q solution. The thermocycling was performed using the 
Eppendorf, Mastercycler epgradient S (Hamburg, Germany). The DNA gel electrophoresis 
(Elite 300 power pack, Wealtec, South Africa) was performed on a 2% agarose gel 
(Whitehead Scientific, Brackenfell, Cape Town), which contained 0.5 µg.ml-1 ethidium 
bromide (Promega, Madison, USA). The loading dye used was Fermentas 6X orange loading 
dye solution (Fermentas UAB, Lithuania). The ready to use 100 bp ladder (Promega, 
Madison, USA) was used as a molecular size marker. A 10% solution of TBE buffer 10X 
(Promega, Madison. USA) was used for the preparation and running of the gels. 
12. Prevalence of antibiotic resistance genes in Acinetobacter baumannii 
isolates in a clinical setting in the Pretoria area, South Africa 
The origins of the Acinetobacter baumannii isolates collected in this study were 58% (56/97) 
from sputum specimens, 7% (7/97) from urine specimens, 11% (11/97) from blood cultures 
and 24% (23/97) from diverse specimens. The A. baumannii isolates collected for this study 
were both imipenem and meropenem resistant with a minimum inhibitory concentration 
(MIC) of >=16. The 97 A. baumannii isolates were subjected to susceptibility testing using the 
Vitek 2 instrument. The panel consisted of 18 antibiotics to determine the overall pattern of 
resistance. The selection of A. baumannii isolates used in this study was based on the Vitek 2 
instrument. Both imipenem and meropenem resistant A. baumannii isolates were included in 
this study. All of the A. baumannii isolates showed 100% resistance to the following antibiotics 
in the panel: ampicillin; amoxicillin/clavulanic acid; cefuroxime; cefuroxime axetil; cefepime; 
imipenem; meropenem; nitrofurantoin and trimethoprim/sulfamethoxazole. The A. baumannii 
clinical isolates were all susceptible (0% resistance) to colistin (Table 2). 
The Hodge test showed that 74% (72/97) of the A. baumannii isolates were positive for 
carbapenemase production and 26% (25/97) of the A. baumannii isolates were negative for 
carbapenemase production (Figure 2). These results are similar to the findings of the study 
conducted in Korea by Lee et al. (2003), which reported a prevalence of 66% positive for 
carbapenemase production, 26% negative for carbapenemase production and 8% data 
unknown.  
The Cloverleaf or Hodge test is cumbersome and imperfect. False positives occur due to 
AmpC and impermeability, not due to β-lactamase production. Weak false positives occur 
due to AmpC hyperproducers. AmpC hydrolysing β-lactams are produced by Gram-
negative bacteria [Presentation by David Livermore on “Detecting carbapenemases” at the 
49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)]. Some A. 
baumannii isolates are resistant to ertapenem, but are rarely resistant to any of the other  
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Antibiotic Tested Percentage resistance
Ampicillin 100% (97/97) 
Amoxicillin/Clavulanic acid 100% (97/97) 
Piperacillin/Tazobactam 99% (96/97) 
Cefuroxime 100% (97/97) 
Cefuroxime Axetil 100% (97/97) 
Cefotaxime 99% (96/97) 
Ceftazidime 49% (48/97) 
Cefepime 100% (97/97) 
Imipenem 100% (97/97) 
Meropenem 100% (97/97) 
Amikacin 25% (24/97) 
Gentamicin 89% (86/97) 
Tobramycin 5% (5/97) 
Nalidixic acid 95% (92/97) 
Ciprofloxacin 91% (88/97) 
Nitrofurantoin 100% (97/97) 
Colistin 0% (0/97) 
Trimethoprim/sulfamethoxazole 100% (97/97) 
Table 2. Antibiotic resistance patterns in Acinetobacter baumannii isolates from a Tertiary 
Academic Hospital  
 
Fig. 2. Hodge or cloverleaf test of three Acinetobacter baumannii isolates 
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carbapenems. The Hodge test is very time consuming to set up and the reading of the results 
is subjective. Some strains produce bacteriocins, which kill the indicator organism 
[Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience 
conference on antimicrobial agents and chemotherapy (ICAAC)]. Beta-lactamase production 
affects the porins of the outer membrane, thus making A. baumannii impermeable to 
antibiotics and therefore resistant to antibiotics e.g. carbapenems [Presentation by David 
Livermore on “Detecting carbapenemases” at the 49th Interscience conference on 
antimicrobial agents and chemotherapy (ICAAC)]. The class of carbapenemase cannot be 
determined by the results of the Modified Hodge test. Some isolates show a slight 
indentation, but do not produce carbapenemase (Standard operating procedure of the 
Department of Health and Human Services, Centres for Disease Control and Prevention: 
“Modified Hodge Test for Carbapenemase Detection in Enterobacteriaceae”). 
The double disk synergy test showed that 33% (32/97) of the A. baumannii isolates were 
susceptible to both ertapenem and EDTA and 19% (18/97) of the isolates did not grow 
(Figure 3). A prevalence of 45% (44/97) was recorded for A. baumannii isolates that were 
ertapenem resistant and EDTA susceptible and a prevalence of 3% (3/97) was recorded for 
both ertapenem and EDTA resistance. These findings are lower than the results of the study 
conducted in Korea by Lee et al. (2003), which reported a prevalence of 94% (75/80) of A. 
baumannii isolates susceptible for both imipenem and EDTA; all the isolates grew in that 
study; 5% (5/97) of the A. baumannii isolates were resistant to imipenem and susceptible to 
EDTA and 0% (0/97) isolates were resistant to both imipenem and EDTA. 
 
Fig. 3. Double disk synergy test of one Acinetobacter baumannii isolate 
EDTA permeabilizes the bacterial cell, is a chelator of zinc and disrupts OXA dimers, which 
may be stabilized by zinc [Presentation by David Livermore on “Detecting carbapenemases” 
Ertapenem 
EDTA 
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at the 49th Interscience conference on antimicrobial agents and chemotherapy (ICAAC)]. 
Therefore EDTA disrupts the function of the carbapenemase producing genes and hence the 
A. baumannii isolates are more susceptible to ertapenem in the presence of EDTA than 
without EDTA. The discrepancies in the results of this study compared to the results of the 
study conducted by Lee et al. (2003) were due to the use of different carbapenems. 
Ertapenem was used in this study, while Lee et al. used imipenem in their study conducted 
in 2003. Imipenem disks perform poorly as a screen for carbapenemases (Clinical and 
Laboratory Standards Institute, 2009) and thus ertapenem was used in this study. 
The A. baumannii clinical specimens were cultured and two different multiplex PCR assays 
were performed on the extracted DNA sample of each isolate. The first multiplex PCR assay 
(Multiplex PCR I) was performed to screen for the presence of the OXA-group genes (OXA-
23, OXA-24, OXA-51 and OXA-58). The second Multiplex PCR assay (Multiplex PCR II) 
screened for the presence of the Metallo--lactamase genes (IMP, VIM, SIM, SPM and GIM). 
Multiplex PCR I showed that 80% (78/97) of the A. baumannii isolates were positive for 
OXA-51, 52% (50/97) were positive for OXA-23, 1% (1/97) were positive for OXA-58 and 2% 
(2/97) were positive for OXA-24 (Figure 4). Figure 5 showed the gel electrophoresis pattern 
of the OXA-51, OXA-23, OXA-58 and OXA-24 genes. 
 
 
 
Fig. 4. Pie chart showing the results of the Multiplex PCR I for the prevalence of the OXA 
genes in the 97 Acinetobacter baumannii isolates obtained from a Tertiary Academic Hospital 
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Fig. 5. Results obtained after Multiplex PCR I was performed, using a 2% agarose gel for the 
detection of OXA genes in the Acinetobacter baumannii isolates. Lanes 2, 3, 4, 5, 7, 9, 10, 11, 12 
and 13 were positive for both OXA 51 and OXA-23. Lane 6 was positive only for OXA-51. 
Lane 8 was positive for OXA-23, OXA-51 and OXA-58. Lanes 1 and 14 contain the molecular 
weight markers (100 bp DNA ladder). 
The multiplex PCR I results showed there were four distinctive strains of A. baumannii 
circulating in a Tertiary Academic hospital in Gauteng, South Africa. The first group of 
strains were positive for both OXA-51 and OXA-23 (52%). The second group of strains was 
positive for OXA-51 (26%) alone. The third group of strains were positive for both OXA-51 
and OXA-24 (2%) and the fourth group of strains were positive for both OXA-51 and OXA-
58 (1%) (Figure 6). 
 
Fig. 6. Pie chart showing the results of the Multiplex PCR I for the four  strains of 
Acinetobacter baumannii circulating in a Tertiary Academic Hospital 
OXA-23 
501 bp 
OXA-51 
353 bp 
OXA-58 
599 bp 
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OXA-51 is an abiquitous or naturally occurring gene within A. baumannii (Merkier & 
Centron, 2006). OXA-51 is a chromosomally located gene, which needs to be regulated 
upstream by ISAba1 to provide resistance [Presentation by David Livermore on “Detecting 
carbapenemases” at the 49th Interscience conference on antimicrobial agents and 
chemotherapy (ICAAC)]. The prevalence of OXA-51 in clinical isolates of A. baumannii in 
this study was 80% (78/97). This figure is lower than the findings of a study conducted in 
Iran by Feizabadi and colleagues (2008), which reported a 100% prevalence of the OXA-51 
gene in clinical isolates of A. baumannii. 
The prevalence of OXA-23 in clinical isolates of A. baumannii in this study was 52% (50/97). 
This finding was similar to the OXA-23 prevalence of 66.5% in the Asia Pacific nations 
(India, China, Thailand, Singapore, Hong kong and Korea) (Mendes et al., 2009). However, 
based on other studies conducted in Iran by Feizabadi and colleagues (2008) who reported a 
prevalence of 36.5% in clinical isolates of A. baumannii the prevalence of OXA-23 varies 
worldwide. OXA-23 forms part of the class D metallo-β-lactamases and is an acquired 
carbapenemase gene, thus a varied prevalence is observed as not all A. baumannii isolates 
will obtain the gene compared to OXA-51 which is a chromosomal carbapenemase gene 
occuring naturally in A. baumannii (Merkier & Centron, 2006). The carbapenemase gene 
occurs in widespread clones and contributes to the multidrug resistant nature of A. 
baumannii [Presentation by David Livermore on “Detecting carbapenemases” at the 49th 
Interscience conference on antimicrobial agents and chemotherapy (ICAAC)]. 
The OXA-24 genes also form part of the class D metallo-β-lactamases and are acquired 
carbapenemase genes, which occur within widespread clones [Presentation by David 
Livermore on “Detecting carbapenemases” at the 49th Interscience conference on 
antimicrobial agents and chemotherapy (ICAAC)]. The prevalence of OXA-24 in A. 
baumannii in this study was 2% (2/97). This finding was similar to the OXA-24 prevalence of 
5.6% in A. baumannii clinical isolates from a study conducted in Thailand, Taiwan and 
Indonesia in 2008 (Mendes et al., 2008). However, a prevalence of 26% of OXA-24 was 
reported in the study conducted by Feizabadi and colleagues in Iran in 2008. The varied 
prevalence results are due to OXA-24 being an acquired gene within A. baumannii and thus 
not all isolates will contain the gene (Merkier & Centron, 2006). 
The prevalence of OXA-58 in clinical isolates of A. baumannii in this study was 1% (1/97). 
This finding was lower than the OXA-58 prevalence of 15% in A. baumannii isolates in the 
study conducted by Feizabadi and colleagues in Iran in 2008. The differences in the results 
of this study and other studies are due to OXA-58 being an acquired carbapenemase gene 
and the presence of this gene within widespread clones Presentation by David Livermore on 
“Detecting carbapenemases” at the 49th Interscience conference on antimicrobial agents and 
chemotherapy (ICAAC)]. 
No metallo-β-lactamase genes were detected in any of the A. baumannii isolates. IMP, VIM, 
SIM, SPM and GIM genes belong to the class B metallo-β-lactamases and are acquired 
carbapenemase genes. IMP (primarily detected in South Korea) and VIM (previously detected 
in China) are the two metallo-β-lactamase genes, which are the most frequently detected genes 
in A. baumannii isolates (Coelho et al., 2006). The prevalence of the metallo-β-lactamase genes is 
generally low within A. baumannii isolates as illustrated in a study by Mendes and colleagues 
(2009) where the prevalence was 0.8% in Taiwan. VIM, SIM, SPM, IMP and GIM have not been 
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detected in South Africa yet. Therefore the results of this study compared with the literature in 
that the selected A. baumannii isolates were negative for all metallo-β-lactamase genes. 
13. Conclusions 
Acinetobacter baumannii is an important opportunistic pathogen and causes a variety of 
nosocomial infections especially within the ICU of the Tertiary Academic Hospital in 
Gauteng, South Africa. The results of the phenotypic analysis in the form of the Hodge test 
and Double disk synergy test were similar to the results obtained from the study conducted 
by Lee et al. in Korea in 2003. The discrepancies with the results of the two studies can be 
largely due to the use of different carbapenem antibiotic disks. The Hodge test is imperfect 
as false positives occur due to AmpC production and impermeability of the bacterium to 
antibiotics due to β-lactamase ability to affect the porins of the outer membrane. 
After completion of this study it is evident that the OXA group of genes (class D 
carbapenemases) are a problem in clinical isolates of A. baumannii from the Tertiary Academic 
Hospital. It was found that OXA-51 genes (80%) and OXA-23 genes (52%) were highly 
prevalent in this study and these prevalence rates were similar to the worldwide prevalence of 
OXA genes, which are widespread in A. baumannii throughout the world (Feizabadi et al., 
2008). Metallo-β-lactamase (MBL) genes were not prevalent in the selected clinical isolates of 
A. baumannii due to the contained spread of the genes and thus no metallo-β-lactamase has 
been detected in South Africa thus far. According to Livermore molecular tests are definitive, 
but a few isolates with strong carbapenemase activity were negative in all molecular tests 
[Presentation by David Livermore on “Detecting carbapenemases” at the 49th Interscience 
conference on antimicrobial agents and chemotherapy (ICAAC)]. 
The multiplex PCR assays proved to be a rapid technique for antimicrobial susceptibility 
testing, however, there is much work to be done in order to investigate the possibilities of 
multiplex PCR assays as an alternative to current antimicrobial susceptibility testing. 
Continuous research and surveillance is necessary to monitor the prevalence of antibiotic 
resistance genes associated with A. baumannii in clinical settings. The ability of A. baumannii 
to grow in biofilms poses a threat concerning the possibilities of the spread of both the 
bacteria and the antibiotic resistance genes, which should be investigated in future research. 
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